Benzinga | May 17, 2021 04:30PM EDT

Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial

* Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent (dupilumab) in children aged 6 to 11 years for the treatment of asthma.

* In a phase 3 trial called Voyage, Dupixent plus standard-of-care asthma therapy significantly cut asthma attacks at Week 24 and improved lung function within two weeks in children ages 6 to 11 with moderate-to-severe asthma, compared with standard care.

* Investigators tested the drug in 408 children, dividing them into two groups, each with different markers of type 2 asthma.

* The Dupixent patients saw an improvement in asthma control at Week 24 as measured on a 0 to 6 scale of symptom severity and disease impact.

* The two groups of Dupixent patients reported score improvements of 1.33 and 1.44 on the scale, respectively, compared with 0.88 and 1.00 for those on placebo.

* The improvement for patients on Dupixent more than doubled the "clinically meaningful threshold of 0.5 points," Sanofi said.

* There was a significant reduction in mean FeNO levels (airway biomarker), to below the threshold for type 2 inflammation, which is 20 parts per billion (ppb).

* Patients taking Dupixent had an average improvement in FeNO levels by -20.59 and -17.84 ppb vs. placebo from baseline to week 12 (p<0.0001 for both values).

* Price Action: REGN shares closed 1.5% higher at $523.73, and SNY shares are 1.42% higher at $53.49 during the market session on the last check Monday.